NASDAQ:VTVT - vTv Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 242.86 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.75
▲ +0.05 (2.94%)

This chart shows the closing price for VTVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New vTv Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTVT

Analyst Price Target is $6.00
▲ +242.86% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for vTv Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 242.86% upside from the last price of $1.75.

This chart shows the closing price for VTVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in vTv Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/24/2021HC WainwrightReiterated RatingBuy$6.00Medium
6/15/2020Northland SecuritiesInitiated CoverageBuy$8.00Medium
5/28/2020Northland SecuritiesInitiated CoverageBuy$8.00Low
3/18/2020HC WainwrightReiterated RatingBuyHigh
2/10/2020HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $6.00High
10/31/2019Northland SecuritiesReiterated RatingBuyLow
10/24/2019Northland SecuritiesReiterated RatingBuy$8.00High
10/9/2019Northland SecuritiesSet Price TargetBuy$8.00Low
9/18/2019Northland SecuritiesSet Price TargetBuy$8.00Low
8/16/2019HC WainwrightReiterated RatingBuy$5.00High
8/1/2019Northland SecuritiesReiterated RatingBuy$8.00High
6/28/2019Northland SecuritiesSet Price TargetBuy$8.00Medium
6/7/2019HC WainwrightReiterated RatingBuy$5.00High
5/30/2019HC WainwrightInitiated CoverageBuy ➝ Buy$5.00High
5/6/2019Northland SecuritiesUpgradeMarket Perform ➝ OutperformMedium
3/18/2019Northland SecuritiesSet Price TargetHold$3.00High
2/27/2019Northland SecuritiesReiterated RatingHold$3.00Low
4/10/2018Roth CapitalDowngradeBuy ➝ Neutral$18.00 ➝ $17.00High
4/10/2018Northland SecuritiesDowngradeOutperform ➝ Market Perform$28.00High
4/10/2018Seaport Global SecuritiesDowngradeBuy ➝ NeutralHigh
4/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$4.00High
4/10/2018Stifel NicolausDowngradeBuy ➝ HoldHigh
3/29/2018Seaport Global SecuritiesInitiated CoverageBuy$14.00High
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$17.00High
2/8/2018Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$28.00Low
12/21/2017Canaccord GenuitySet Price TargetBuy$15.00Low
11/8/2017CitigroupReiterated RatingaddN/A
11/3/2017Stifel NicolausReiterated RatingBuy$12.00N/A
8/4/2017Canaccord GenuityReiterated RatingBuy$15.00Low
8/4/2017HC WainwrightSet Price TargetBuy$13.00Low
5/4/2017HC WainwrightSet Price TargetBuy$13.00Low
3/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$24.00Low
3/30/2017HC WainwrightReiterated RatingBuy$13.00High
2/28/2017HC WainwrightReiterated RatingBuy$13.00N/A
2/28/2017Canaccord GenuityReiterated RatingBuyN/A
12/18/2016Canaccord GenuitySet Price TargetBuy$15.00N/A
12/16/2016HC WainwrightReiterated RatingBuy$13.00N/A
12/15/2016Stifel NicolausSet Price TargetBuy$14.00N/A
11/8/2016HC WainwrightReiterated RatingBuyN/A
10/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$24.00N/A
9/26/2016HC WainwrightInitiated CoverageBuy$13.00N/A
(Data available from 9/23/2016 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
vTv Therapeutics logo
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
Read More

Today's Range

Now: $1.75
Low: $1.71
High: $1.75

50 Day Range

MA: $1.87
Low: $1.68
High: $2.17

52 Week Range

Now: $1.75
Low: $1.44
High: $4.75

Volume

4,947 shs

Average Volume

3,335,755 shs

Market Capitalization

$145.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of vTv Therapeutics?

The following Wall Street analysts have issued research reports on vTv Therapeutics in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for VTVT.

What is the current price target for vTv Therapeutics?

1 Wall Street analysts have set twelve-month price targets for vTv Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 242.9%. HC Wainwright has the highest price target set, predicting VTVT will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for vTv Therapeutics in the next year.
View the latest price targets for VTVT.

What is the current consensus analyst rating for vTv Therapeutics?

vTv Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VTVT will outperform the market and that investors should add to their positions of vTv Therapeutics.
View the latest ratings for VTVT.

What other companies compete with vTv Therapeutics?

How do I contact vTv Therapeutics' investor relations team?

vTv Therapeutics' physical mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company's listed phone number is (336) 841-0300 and its investor relations email address is [email protected] The official website for vTv Therapeutics is www.vtvtherapeutics.com.